Specific pharmacological inhibition of LRH-1 resulted in reduced activation- and LRH-1-induced FasL expression and cytotoxicity in T cells, and inhibited FasL-dependent liver damage in the context of experimental hepatitis in vivo. The gene discussed is NR5A2; the disease is Hepatitis.